Creating immune privilege: Active local suppression that benefits friends, but protects foes

Nature Reviews Immunology

Volumn 8, Issue 1, 2008, Pages 74-80

  Mellor, Andrew L ^a   Munn, David H ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS LIGAND; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; PROTEIN PDL1; PROTEIN PDL2; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTIGENICITY; CD4+ CD25+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; NONHUMAN; NOTE; PRIORITY JOURNAL; REGULATORY MECHANISM; T LYMPHOCYTE ACTIVATION; TH2 CELL; TH3 CELL; TISSUE TRANSPLANTATION; TUMOR CELL;

ANIMALS; HUMANS; IMMUNE TOLERANCE; INFECTION; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 37549061827     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2233     Document Type: Note

References (75)

1. Parmiani, G., De Filippo, A., Novellino, L. & Castelli, C. Unique human tumor antigens: immunobiology and use in clinical trials. J. Immunol. 178, 1975-1979 (2007).
2. Simpson, E. A historical perspective on immunological privilege. Immunol. Rev. 213, 12-22 (2006).
3. Caspi, R. R. Ocular autoimmunity: the price of privilege? Immunol. Rev. 213, 23-35 (2006).
4. Niederkorn, J. Y. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nature Immunol. 7, 354-359 (2006).
5. Carson, M. J., Doose, J. M., Melchior, B., Schmid, C. D. & Ploix, C. C. CNS immune privilege: hiding in plain sight. Immunol. Rev. 213, 48-65 (2006).
6. Fijak, M. & Meinhardt, A. The testis in immune privilege. Immunol. Rev. 213, 66-81 (2006).
7. Medawar, P. B. Some immunological and endocrinological problems raised by evolution of viviparity in vertebrates. Symp. Soc. Exp. Biol. 7, 320-328 (1953).
8. Waldmann, H. et al. Regulatory T cells and organ transplantation. Semin. Immunol. 16, 119-126 (2004).
9. Tafuri, A., Alferink, J., Moller, P., Hammerling, G. J. & Arnold, B. T cell awareness of paternal alloantigens during pregnancy. Science 270, 630-633 (1995).
10. Jiang, S. P. & Vacchio, M. S. Multiple mechanisms of peripheral T cell tolerance to the fetal "allograft". J. Immunol. 160, 3086-3090 (1998).
11. + T cells specific for paternal MHC class I accumulate during pregnancy. J. Repro. Immunol. 40, 47-62 (1998).
12. Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191-1193 (1998).
13. Mellor, A. L. et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nature Immunol. 2, 64-68 (2001).
14. Aluvihare, V. R., Kallikourdis, M. & Betz, A. G. Regulatory T cells mediate maternal tolerance to the fetus. Nature Immunol. 5, 266-271 (2004).
15. Crispe, I. N. et al. Cellular and molecular mechanisms of liver tolerance. Immunol. Rev. 213, 101-118 (2006).
16. + Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity 16, 183-191 (2002).
17. + regulatory T cells in the regional lymph node. J. Exp. Med. 202, 771-781 (2005).
18. Kraal, G., Samsom, J. N. & Mebius, R. E. The importance of regional lymph nodes for mucosal tolerance. Immunol. Rev. 213, 119-130 (2006).
19. Loser, K. et al. IL-10 controls ultraviolet-induced carcinogenesis in mice. J. Immunol. 179, 365-371 (2007).
20. Iweala, O. I. & Nagler, C. R. Immune privilege in the gut: the establishment and maintenance of nonresponsiveness to dietary antigens and commensal flora. Immunol. Rev. 213, 82-100 (2006).
21. Matzinger, P. Friendly and dangerous signals: is the tissue in control? Nature Immunol. 8, 11-3 (2007).
22. Matzinger, P. The danger model: a renewed sense of self. Science 296, 301-305 (2002).
23. Medzhitov, R. & Janeway, C. A., Jr. Decoding the patterns of self and nonself by the innate immune system. Science 296, 298-300 (2002).
24. Sansonetti, P. J. & Di Santo, J. P. Debugging how bacteria manipulate the immune response. Immunity 26, 149-161 (2007).
25. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 175, 5601-5605 (2005).
26. Wingender, G. et al. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur. J. Immunol. 36, 12-20 (2006).
27. Reis e Sousa, C. Dendritic cells in a mature age. Nature Rev. Immunol. 6, 476-483 (2006).
28. Hackstein, H. & Thomson, A. W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nature Rev. Immunol. 4, 24-34 (2004).
29. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769-779 (2001).
30. + T cell tolerance. Immunity 18, 713-720 (2003).
31. Mellor, A. L. & Munn, D. H. IDO expression in dendritic cells: tolerance and tryptophan catabolism. Nature Rev. Immunol. 4, 762-774 (2004).
32. Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005).
33. Okazaki, T. & Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27, 195-201 (2006).
34. Ferguson, T. A. & Griffith, T. S. A vision of cell death: FasL and immune privilege - 10 years later. Immunol. Rev. 213, 228-238 (2006).
35. Keir, M. E., Francisco, L. M. & Sharpe, A. H. PD-1 and its ligands in T-cell immunity. Curr. Opin. Immunol. 19, 309-314 (2007).
36. Munn, D. H. et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290 (2004).
37. Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 1-10 (2005).
38. Fallarino, F. et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells. J. Immunol. 176, 6752-6761 (2006).
39. Sharma, M. D. et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117, 1-13 (2007).
40. Rodriguez, P. C., Quiceno, D. G. & Ochoa, A. C. L-arginine availability regulates T-lymphocyte cell-cycle progression. Blood 109, 1568-1573 (2007).
41. Morelli, A. E. & Thomson, A. W. Tolerogenic dendritic cells and the quest for transplant tolerance. Nature Rev. Immunol. 7, 610-621 (2007).
42. Mahnke, K., Johnson, T. S., Ring, S. & Enk, A. H. Tolerogenic dendritic cells and regulatory T cells: a two-way relationship. J. Dermatol. Sci. 46, 159-167 (2007).
43. + regulatory T cells by targeting of antigens to immature dendritic cells. Blood 101, 4862-4869 (2003).
44. Ochando, J. C. et al. Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. Nature Immunol. 7, 652-662 (2006).
45. + natural regulatory T cells are specific for microbial antigens. J. Exp. Med. 203, 777-788 (2006).
46. Zhou, F., Rouse, B. T. & Huang, L. Induction of cytotoxic T lymphocytes in vivo with protein antigen entrapped in membranous vehicles. J. Immunol. 149, 1599-1604 (1992).
47. Zhou, G. & Levitsky, H. I. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J. Immunol. 178, 2155-2162 (2007).
48. Cobbold, S. P. et al. Immune privilege induced by regulatory T cells in transplantation tolerance. Immunol. Rev. 213, 239-255 (2006).
49. Tang, Q. & Bluestone, J. A. Plasmacytoid DCs and Treg cells: casual acquaintance or monogamous relationship? Nature Immunol. 7, 551-553 (2006).
50. Rudensky, A. Y. & Campbell, D. J. In vivo sites and cellular mechanisms of T reg cell-mediated suppression. J. Exp. Med. 203, 489-492 (2006).
51. Dunn, G. P., Old, L. J. & Schreiber, R. D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21, 137-148 (2004).
52. Balkwill, F. & Mantovani, A. Inflammation and cancer: back to Virchow? Lancet 357, 539-545 (2001).
53. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol. 4, 941-952 (2004).
54. Munn, D. H. & Mellor, A. L. Tumor draining lymph nodes as a site of tolerance induction. Immunol. Rev. 213, 146-158 (2006).
55. van der Most, R. G., Currie, A., Robinson, B. W. & Lake, R. A. Cranking the immunologic engine with chemotherapy: using context to drive tumor antigen cross-presentation towards useful antitumor immunity. Cancer Res. 66, 601-604 (2006).
56. Zhou, G., Drake, C. G. & Levitsky, H. I. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107, 628-636 (2006).
57. + T cell tolerance in cancer. Nature Med. 13, 828-835 (2007).
58. Gajewski, T. F. et al. Immune resistance orchestrated by the tumor microenvironment. Immunol. Rev. 213, 131-145 (2006).
59. Zou, W. Regulatory T cells, tumour immunity and immunotherapy. Nature Rev. Immunol. 6, 295-307 (2006).
60. Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Med. 13, 1050-1059 (2007).
61. Zhang, B. et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J. Exp. Med. 204, 49-55 (2007).
62. Peters, N. & Sacks, D. Immune privilege in sites of chronic infection: Leishmania and regulatory T cells. Immunol. Rev. 213, 159-179 (2006).
63. Trinchieri, G. Interleukin-10 production by effector T cells: Th1 cells show self control. J. Exp. Med. 204, 239-243 (2007).
64. Belkaid, Y. et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194, 1497-1506 (2001).
65. + regulatory T cells control Leishmania major persistence and immunity. Nature 420, 502-507 (2002).
66. + regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J. Exp. Med. 203, 2451-2460 (2006).
67. Popov, A. et al. Indoleamine 2,3-dioxygenase-expressing dendritic cells form suppurative granulomas following Listeria monocytogenes infection. J. Clin. Invest. 116, 3160-3170 (2006).
68. Grant, R. S. et al. Induction of indoleamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J. Virol. 74, 4110-4115 (2000).
69. + T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells. Blood 109, 3351-3359 (2007).
70. + dendritic cells. Eur. J. Immunol. 37, 1064-1071 (2007).
71. + plasmacytoid dendritic cells. Curr. Drug Metab. 8, 209-216 (2007).
72. Chambers, C. A., Kuhns, M. S., Egen, J. G. & Allison, J. P. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 19, 565-594 (2001).
73. Miyara, M. & Sakaguchi, S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13, 108-116 (2007).
74. Nowak, M. & Stein-Streilein, J. Invariant NKT cells and tolerance. Int. Rev. Immunol. 26, 95-119 (2007).
75. Mizoguchi, A. & Bhan, A. K. A case for regulatory B cells. J. Immunol. 176, 705-710 (2006).